Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 05 07 2018
accepted: 18 01 2019
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 24 9 2020
Statut: epublish

Résumé

This study analyzes the association of excessive energy intake and caloric restriction with breast cancer (BC) risk taking into account the individual energy needs of Spanish women. We conducted a multicenter matched case-control study where 973 pairs completed lifestyle and food frequency questionnaires. Expected caloric intake was predicted from a linear regression model in controls, including calories consumed as dependent variable, basal metabolic rate as an offset and physical activity as explanatory. Overeating and caloric restriction were defined taking into account the 99% confidence interval of the predicted value. The association with BC risk, overall and by pathologic subtype, was evaluated using conditional and multinomial logistic regression models. While premenopausal women that consumed few calories (>20% below predicted) had lower BC risk (OR = 0.36; 95% CI = 0.21-0.63), postmenopausal women with an excessive intake (≥40% above predicted) showed an increased risk (OR = 2.81; 95% CI = 1.65-4.79). For every 20% increase in relative (observed/predicted) caloric intake the risk of hormone receptor positive (p-trend < 0.001) and HER2+ (p-trend = 0.015) tumours increased 13%, being this figure 7% for triple negative tumours. While high energy intake increases BC risk, caloric restriction could be protective. Moderate caloric restriction, in combination with regular physical activity, could be a good strategy for BC prevention.

Identifiants

pubmed: 30846706
doi: 10.1038/s41598-019-39346-4
pii: 10.1038/s41598-019-39346-4
pmc: PMC6405854
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3904

Références

J Clin Oncol. 2010 Sep 10;28(26):4058-65
pubmed: 20697088
Adv Nutr. 2016 Jul 15;7(4):690-705
pubmed: 27422504
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Cell Cycle. 2016 Sep;15(17):2265-74
pubmed: 27027731
Diabetes Obes Metab. 2011 Dec;13(12):1063-72
pubmed: 21733057
JAMA. 2012 Jan 4;307(1):47-55
pubmed: 22215165
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Ageing Res Rev. 2017 Oct;39:36-45
pubmed: 27544442
Methods Mol Biol. 2009;472:191-215
pubmed: 19107434
Breast Cancer Res Treat. 2006 May;97(1):97-106
pubmed: 16319973
Eur J Public Health. 2015 Oct;25(5):857-63
pubmed: 25767095
PLoS One. 2016 Sep 19;11(9):e0158003
pubmed: 27643873
Public Health Nutr. 2015 Mar;18(4):571-81
pubmed: 25416919
Breast Cancer Res Treat. 2013 Jan;137(2):541-51
pubmed: 23225141
Gynecol Oncol. 2013 Sep;130(3):609-14
pubmed: 23747837
Int J Obes (Lond). 2013 Oct;37(10):1364-70
pubmed: 23318720
Proc Nutr Soc. 2012 May;71(2):263-75
pubmed: 22414375
J Carcinog. 2011;10:21
pubmed: 22013391
Methods Mol Biol. 2009;472:57-88
pubmed: 19107429
Nutr J. 2013 Feb 19;12:26
pubmed: 23421854
Gynecol Oncol. 2017 Mar;144(3):577-585
pubmed: 28057355
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):334-41
pubmed: 16492925
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Cancer. 2001 Sep 15;92(6):1638-49
pubmed: 11745243
Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1496-501
pubmed: 15941962
Trends Pharmacol Sci. 2010 Feb;31(2):89-98
pubmed: 20097433
Br J Cancer. 2014 Sep 23;111(7):1454-62
pubmed: 25101568
Endocr Relat Cancer. 2015 Dec;22(6):R365-86
pubmed: 26373570
N Engl J Med. 1992 Dec 31;327(27):1893-8
pubmed: 1454084
Cancer Metab. 2013 Mar 07;1(1):10
pubmed: 24280167
Int J Obes (Lond). 2011 May;35(5):714-27
pubmed: 20921964
Cancer Res. 2017 May 1;77(9):2500-2511
pubmed: 28373182

Auteurs

Virginia Lope (V)

National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Miguel Martín (M)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Adela Castelló (A)

National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Amparo Ruiz (A)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Instituto Valenciano de Oncología, Valencia, Spain.

Ana Mª Casas (AM)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Virgen del Rocío, Sevilla, Spain.

José Manuel Baena-Cañada (JM)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Puerta del Mar, Cádiz, Spain.

Silvia Antolín (S)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.

Manuel Ramos-Vázquez (M)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Centro Oncológico de Galicia, A Coruña, Spain.

José Ángel García-Sáenz (JÁ)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Clínico San Carlos, Madrid, Spain.

Montserrat Muñoz (M)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Clinic i Provincial, Barcelona, Spain.

Ana Lluch (A)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
Hospital Clínico de Valencia, Valencia, Spain.

Ana de Juan-Ferré (A)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Marqués de Valdecilla, Santander, Spain.

Carlos Jara (C)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Fundación Hospital de Alcorcón, Madrid, Spain.

Pedro Sánchez-Rovira (P)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Complejo Hospitalario de Jaén, Jaén, Spain.

Antonio Antón (A)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Universitario Miguel Servet, Zaragoza, Spain.

José Ignacio Chacón (JI)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Hospital Virgen de la Salud, Toledo, Spain.

Angels Arcusa (A)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Consorci Sanitari de Terrassa, Barcelona, Spain.

Mª Angeles Jimeno (MA)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Susana Bezares (S)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Jesús Vioque (J)

Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
Universidad Miguel Hernández, ISABIAL, Alicante, Spain.

Eva Carrasco (E)

GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Beatriz Pérez-Gómez (B)

National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Marina Pollán (M)

National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain. mpollan@isciii.es.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain. mpollan@isciii.es.
GEICAM Spanish Breast Cancer Group, Madrid, Spain. mpollan@isciii.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH